Victory in EPO opposition safeguards patent for breakthrough hyperkalaemia drug
In 2018, we preserved the European patent in a successful defence in EPO opposition proceedings filed by two generic pharmaceutical manufacturers.
In 2018, we preserved the European patent in a successful defence in EPO opposition proceedings filed by two generic pharmaceutical manufacturers.
We have worked with KLAW Products and Gall Thomson Environmental, two innovative subsidiary companies of engineering group Signum Technology, for many years. Combining design, engineering, patent and trade mark expertise, our team has played an instrumental role in building a strong IP portfolio for these companies.
We have acted for a company in the fuel cell sector for many years and worked with them to grow their portfolio. From small beginnings we developed a close relationship with both their in-house team and the inventors to grow their patent portfolio.
In one of the most significant patent cases of 2018/19, we fielded a 15-strong multidisciplinary team of specialist IP solicitors and patent attorneys to secure a global settlement for Alnylam Pharmaceuticals Inc.
Our biotech team brought to bear their deep scientific understanding and legal experience in patent drafting and global filing and prosecution strategy to secure commercially-focussed patent protection.
Instructed by the subsidiary of a world leader in food production focussing on high-quality nutrition products for the global market, we assisted the client in considering the merits and negotiating the terms of a global patent licence.
The patents and design registrations successfully obtained by the team at Potter Clarkson put the necessary IP protection in place to enable Sanandco to commercialise its product in its most commercially important territories.
The IP solicitors and patent attorneys in our specialist energy and cleantech team are the long-standing representatives for a rapidly growing sustainable energy manufacturer pioneering the use of green hydrogen technology.
We have been working with Alligator Bioscience AB, a Swedish SME specialising in the development of antibody-based therapeutics for cancer treatment since the company’s formation in 2001.